

Professor Robin Wood, a leading physician in the field of HIV treatment and infectious disease research, is the Director of the Desmond Tutu HIV Centre (DTHC) at the Institute of Infectious Diseases and Molecular Medicine, University of Cape Town.

He is presently a member of the governing council of the International AIDS Society and was a founding member of the Southern African HIV Clinicians Society. He has been a technical adviser to the World Health Organization and helped develop new research and clinical trial protocols for five National Institutes of Health networks, including the Comprehensive International Program of Research on AIDS. He has been principal investigator and co-investigator of funding grants from the Doris Duke Charitable Foundation and a recipient of a research funding grant from "Secure the Future" Bristol Myers Squibb. He has authored or co-authored 10 book chapters, has published 220 scientific letters, papers and reviews in peer-reviewed journals, had been a member of the editorial boards of the South African Journal of Epidemiology & Infection and the South African Journal of HIV Medicine, academic editor for Plos Medicine and continues as a scientific reviewer for 24 prominent national and international peer-reviewed journals and the Wellcome Trust UK.

He is co-chair of the Clinical Science Track for the 5<sup>th</sup> IAS Pathogenesis Treatment & Prevention Conference (Cape Town, 2009), has been a member of Scientific Advisory Board for the IAS Pathogenesis and Treatment Conference (Rio de Janeiro, 2006) and member of the Scientific Advisory Boards for International AIDS Conferences (Geneva 1998, Durban 2000 and Barcelona 2002).

Professor Wood is a visiting scientist at Harvard Medical School; a member of the scientific advisory board of the Global AIDS Prevention Model and TB/HIV modelling projects at Harvard University; and a clinical collaborator of the microsimulation modelling of HIV and TB epidemics at the DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis at Stellenbosch University. In South Africa, he has been a technical advisor on antiretroviral therapy and HIV management to the Anglo American, Gold Fields of South Africa, Daimler Benz, Catholic Bishops Antiretroviral therapy programs. He has also led the development of a number of South African national guidelines regarding the use of antiretrovirals, including for adult treatment and occupational and non-occupational post-exposure prophylaxis (2002, 2003). He is a recognized expert witness on HIV-related matters and has acted on several occasions as medical advisor and expert witness to the Treatment Action Campaign, including actions in the South African Constitutional Court and Competitions Tribunal. He is overall Principal Investigator of the Cape Town Clinical Trials Unit (CTU) and Site Leader for the DTHC Clinical Research Site. He chairs the Cape Town CTU Management Committee and has overall responsibility for all aspects of CTU operations. He has been Principal Investigator to more than 40 other local research projects within the DTHC.